TITLE

Vivus Taps Deerfield to Fund Viagra Rival

AUTHOR(S)
Schachter, Ken
PUB. DATE
April 2008
SOURCE
Red Herring;4/4/2008, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on an agreement formed by drug development firm Vivus with Deerfield Management to inject $30 million into the clinical trial of a next-generation compound that aims to compete with Viagra. Vivus turned to the life sciences investment firm to get funding for the phase three clinical trial of the erectile dysfunction drug avanafil. Under the agreement, Deerfield will give $20 million to Vivus within the first 18 months.
ACCESSION #
36834899

 

Related Articles

  • Deerfield Deal Secures $30M for Vivus' Avanafil Phase III Trials. Boggs, Jennifer // BioWorld Today;4/7/2008, Vol. 19 Issue 67, p1 

    The article reports on the $30 million funding agreement of Vivus Inc. with Deerfield Management for the pivotal studies of its erectile dysfunction drug avanafil. Under the deal, a royalty interest on sales of MUSE will be granted by Vivus to Deerfield and the latter would also get a royalty...

  • Dynavax Restarting Tolamba Program In Ragweed; Gets $30M. Boggs, Jennifer // BioWorld Today;7/20/2007, Vol. 18 Issue 140, p1 

    The article discusses the second Phase III study of Tolamba, an immunostimulatory drug developed by Dynavax Technologies Corp. The study was stalled due to a difficulty encountered in determining ragweed-specific allergy response. With the $30 million financing agreement from Deerfield...

  • Vivus drug ineffective in premature ejaculation.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p26 

    Reports on the result of a clinical trial indicating the failure of an investigational compound VI-0162, a drug developed by U.S.-based Vivus Inc., to demonstrate an increase in the time to ejaculation. Result of previous studies suggesting that the drug was associated with an increased time to...

  • Array Gets $40M Funding from Deerfield.  // Bioworld Week;5/25/2009, Vol. 17 Issue 21, p4 

    The article reports on the $40 million funding commitment received by Boulder, Colorado-based Array BioPharma Inc. from Deerfield Management. The funding is indicated to advance the developed program pipeline of small-molecule drug from Array. According to Array, calendar year 2009 had been set...

  • Hard as hell. Baguley, Darren // Bulletin with Newsweek;7/29/2003, Vol. 121 Issue 6383, p68 

    Facing up to sexual dysfunction is a challenge most men will have to face much as they would prefer to ignore it. Viagra has dominated Australia's $50m per year Erectile dysfunction (ED) market since its launch in 1998. The Viagra patents are expiring and new tablets, such as Eli Lilly's Cialis...

  • Vivus targets Viagra-averse to rebuild share. Goetzl, David // Advertising Age;5/3/1999, Vol. 70 Issue 19, p24 

    Reports on the effect Viagra, the impotency treatment, had on Vivus, a company which marketed its own anti-impotency drug treatment. Statistics on the financial problems Vivus had after Viagra became available; Efforts to improve the company's status in 1999.

  • UROGENITAL SYSTEM: 17D Erectile dysfunction.  // MPR - Pharmacist's Edition;Fall2011, Vol. 5 Issue 3, p283 

    The article offers information on various medicine for erectile dysfunction treatment. It says that Caverject from Pfizer Inc. is the Prostaglandin which used to treat and diagnose erectile dysfunction in adults. It adds that Muse from Vivus Inc. is used to treat erectile dysfunction in adults....

  • Hana Stock Gets A Rise With $30M Loan Pact. Morrison, Trista // BioWorld Today;11/1/2007, Vol. 18 Issue 213, p2 

    The article reports on the increase in stock price of Hana Biosciences Inc. after it signed a loan agreement with Deerfield Management. The share price posted an increase of 14 percent on Nasdaq. The loan agreement will provide Hanna up to $30 million in financing over a three-year period. The...

  • VIVUS INITIATES PREMATURE EJACULATION CLINICAL TRIAL.  // Biotech Business;Jan2003, Vol. 16 Issue 1, p8 

    No abstract available.

Share

Read the Article

Other Topics